Paraoxonase (PON1) 55 and 192 polymorphism and its effects to oxidant-antioxidant system in Turkish patients with type 2 diabetes mellitus

Physiological Research

Volumn 54, Issue 3, 2005, Pages 287-293

  Agachan, B ^a   Yilmaz, H ^a   Ergen, H A ^a   Karaali, Z E ^b   Isbir, Turgay ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b Taksim State Hospital   (Turkey)

Author keywords

Conjugated dienes; GSH; Paraoxonase; Polymorphism; TBARS; Turkish population; Type 2 diabetes mellitus

Indexed keywords

ANTIOXIDANT; ARGININE; ARYLDIALKYLPHOSPHATASE; GLUTAMINE; GLUTATHIONE; LEUCINE; OXIDIZING AGENT; THIOBARBITURIC ACID;

ADULT; AGAR GEL ELECTROPHORESIS; AGED; ARTICLE; CONTROLLED STUDY; ENZYME POLYMORPHISM; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SPECTROPHOTOMETRY; TURKEY (REPUBLIC);

ARYLDIALKYLPHOSPHATASE; DIABETES MELLITUS, TYPE 2; DNA MUTATIONAL ANALYSIS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; GLUTATHIONE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; REACTIVE OXYGEN SPECIES; RISK ASSESSMENT; RISK FACTORS; THIOBARBITURIC ACID REACTIVE SUBSTANCES; TURKEY;

EID: 21844472565     PISSN: 08628408     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. ADKINS S, GAN KN, MODY M, LA DU BN: Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet 52: 598-608, 1993.
2. AGACHAN B, YILMAZ H, KARAALI Z, ISBIR T: Paraoxonase 55 and 192 polymorphism and its relationship to serum paraoxonase activity and serum lipids in Turkish patients with non-insulin dependent diabetes mellitus. Cell Biochem Funct 22: 163-168, 2004.
3. ANTIKAINEN M, MURTOMÄKI S, SYVÄNNE M, PAHLMAN R, TAHVANAINEN E, JAUHIANEN M, FRICK MH, EHNHOLM C: The Gln-Arg191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with risk of coronary artery disease in Finns. J Clin Invest 98: 883-885, 1996.
4. AVIRAM M, BILLECKE S, SORENSON R, BISGAIER C, NEWTON R, ROSENBLAT M, EROGUL J, HSU C, DUNLOP C, LA DU BN: Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities. Arterioscler Thromb Vasc Biol 18: 1617-1624, 1998a.
5. AVIRAM M, RONSENBLAT M, BISGAIER CL, NEWTON RS, PRIMO-PARMO SL, LA DU BN: Paraoxonase inhibits high-density lipoprotein and preserves its functions: a possible peroxidative role for paraoxonase. J Clin Invest 101: 1581-1590, 1998b.
6. AVIRAM M, ROSENBLAT M, BILLECKE S, EROGUL J, SORENSON R, BISGAIER CL, NEWTON RS, LA DU BN: Human serum paraoxonase (PON1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic Biol Med 26: 892-904, 1999.
7. BAYNES JW, THORPE SR: Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 48: 1-9, 1999.
8. BERLINER JA, HABERLAND ME: Role of oxidized low density lipoprotein in atherogenesis. Curr Opin Lipidol 4: 373-381, 1991.
9. BLATTER GARIN MC, JAMES RW, DUSSOIX P, BLANCHE H, PASSA P, FROGUEL P, RUIZ J: Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J Clin Invest 99: 62-66, 1997.
10. CAO H, GIRARD-GLOBBA A, BERTHEZENE F, MOULIN P: Paraoxonase protection of LDL against peroxidation is independent of its esterase activity towards paraoxon and is unaffected by the Q-R genetic polymorphism. J Lipid Res 40: 133-139, 1999.
11. DORMANDY TL, WICKENS DG: The experimental and clinical pathology of diene conjugation. Chem Phys Lipids 45: 353-64, 1987.
12. ECKERSON HW, WYTE CM, LA DU BN: The human serum paraoxonase/arylesterase polymorphism. Identification of phenotypes by their response to salts. Am J Hum Genet 35: 214-227, 1983.
13. FAIRBANKS VF, KLEE GG: Biochemical aspects of hematology. In: Textbook of Clinical Chemistry, TIETZ WB (ed), Saunders, Philadelphia, 1991, pp 1640-1645.
14. GIUGLIANO D, CERIELLO A, PAOLISSO G: Oxidative stress and diabetic vascular complications. Diabetes Care 19: 257-267, 1996.
15. GRIESMACHER A, KINDHAUSER M, ANDERT SE, SCHREINER W, TOMA C, KNOEBL P, PIETSCEHMANN P, PRAGER R, SCHANACK C, SCHERNTHANER G, MUELLER MM: Enhanced serum levels of Thiobarbituric acid reactive substances in diabetes mellitus. Am J Med 98: 469-475, 1995.
16. HERRMANN SM, BLANC H, POIRIER O, ARVEILER D, LUC G, EVANS A, MARQUES-VIDAL P, BARD JM, CAMBIEN F: The Gln/Arg polymorphism of human paraoxonase (PON 192) is not related to myocardial infarction in the ECTIM study. Atherosclerosis 126: 299-304, 1996.
17. HUMBERT R, ADLER DA, DISTECHE CM, HASSETT C, OMIECINSKI CJ, FURLONG CE: The molecular basis of the human serum paraoxonase activity polymorphism. Nature Genet 3: 73-76, 1993.
18. KAJI H, JURASAKI M, ITO K: Increased lipid peroxide value and glutathione peroxidase activity in blood plasma of Type 2 (non-insulin-dependent) diabetic women. Klin Wochenschr 63: 765-768, 1985.
19. LA DU B: Human serum paraoxonase/arylesterase. In: Pharmacogenetics of Drug Metabolism. WKALOW (ed), Pergamon Press, New York, 1992, pp 51-91.
20. MACKNESS MI, ARROL S, DURRINGTON PN: Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 286: 152-154, 1991a.
21. MACKNESS MI, HARTY D, BHATNAGAR D, WINOCOUR PH, ARROL S, ISHOLA M, DURRINGTON PN: Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. Atherosclerosis 86: 193-199, 1991b.
22. MACKNESS MI, ABBOTT CA, ARROL S, DURRINGTON PN: The role of high density and lipid-soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation Biochem J 294: 829-835, 1993a.
23. MACKNESS MI, ARROL S, ABBOTT CA, DURRINGTON PN: Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 104: 129-135, 1993b.
24. MACKNESS B, MACKNESS MI, ARROL S, TURKIE W, DURRINGTON PN: Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Lett 423: 57-60, 1998a.
25. MACKNESS B, MACKNESS MI, ARROL S, TURKIE W, JULIER K, ABUASHA B, MILLER JE, BOULTON AJ, DURRINGTON PN: Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus. Atherosclerosis 139: 341-349, 1998b.
26. MCELVEEN J, MACKNESS MI, COLLEY CM, PEARD T, WARNER S, WALKER CH: Distribution of paraoxon hydrolytic activity in the serum of patients after myocardial infarction. Clin Chem 32: 671-673, 1986.
27. MILLER SA, DYKES DD, POLESKY HS: Simples salting out procedure for extracting DNA from human nucleated cells. Nucleic Acid Res 16: 1215, 1988.
28. MOORADIAN AD: Increased serum conjugated dienes in elderly diabetic patients. J Am Geriatr Soc 39: 571-574, 1991.
29. NEVIN DN, ZAMBON A, FURLONG CE, RICHTER RJ, HUMBERT R, HOKANSON JE, BRUNZELL JD: Paraoxonase genotypes, lipoprotein lipase activity, and HDL. Arterioscler Thromb Vasc Biol 16: 1243-1249, 1996.
30. ODAWARA M, TACHI Y, YAMASHITA K: Paraoxonase polymorphism (Gln192-Arg) is associated with coronary heart disease in Japanese non-insulin-dependent diabetic patients. J Clin Endocrinol Metab 82: 2257-2260, 1997.
31. PFOHL M, KOCH M, ENDERLE MD, KÜHN R, FÜLLHASE J, KARSCH KR, HÄRTNG HU: Paraoxonase 192 Gln/Arg gene polymorphism, coronary artery disease, and myocardial infarction in type 2 diabetes. Diabetes 48: 623-627, 1999.
32. REPORT OF WHO CONSULTATION: Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. WHO, Geneva, 1999.
33. RUIZ J, BLANCHE H, JAMES RW, BLATTER-GARIN MC, VAISSE C, CHARPENTIER G, COHEN N, MORABIA A, PASSA P, FROGUEL P: The polymorphism (Gln-Arg 192) of the high-density lipoprotein-bound enzyme paraoxonase is an independent cardiovascular risk factor in non-insulin dependent diabetic patients. Lancet 346: 869-872, 1995.
34. SAKAI T, MATSUURA B, ONJI M: Serum paraoxonase activity and genotype distribution in Japanese patients with diabetes mellitus. Intern Med 37: 581-584, 1998.
35. SALONEN JT, MALIN R, TUORNAINEN TP, NYYSSONEN K, LAKKA TA, LEHTIMAKI T: Polymorphism in high density lipoprotein paraoxonase gene and risk of acute myocardial infarction in men: prospective nested case-control study. Br Med J 319: 487-489, 1999.
36. SANGHERA DK, SAHA N, ASTON CE, KAMBOH MI: Genetic polymorphisms of paraoxonase and the risk of coronary heart disease. Arterioscler Thromb Vasc Biol 17: 1067-1073, 1997.
37. SERRATO M, MARIAN AL: A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary heart disease. J Clin Invest 96: 3005-3008, 1995.
38. STEINBERG D, PARTHASARATHY S, CAREW TE, KHOO JC, WITZTUM JL: Beyond cholesterol: modifications of low density lipoprotein that increase its atherogenicity. N Engl J Med 320: 915-924, 1989.
39. SUEHIRO T, NAKATICHI Y, YAMARNOTO M, ARII K, ITOH H, HAMASHIGE N, HASHIMOTO K: Paraoxonase gene polymorphism in Japanese subjects with coronary heart disease. Int J Cardiol 15: 69-73, 1996.
40. YAGI K: Lipid peroxides and human diseases. Chem Phys Lipids 45: 337-351, 1987.